Insys in Focus on Subsys Worries - Analyst Blog

By
A A A

Insys Therapeutics, Inc. 's ( INSY ) shares have been under pressure recently on news regarding prescribing patterns for Subsys. The stock price of the company tumbled 17.41% and 15.45% in the last two consecutive trading sessions.

Why is Insys in the Spotlight?

Insys came into focus after a website, mlive.com, reported that a Michigan-based neurologist, Dr. Gavin Awerbuch, was charged of health care fraud and distribution of controlled substances. The charges sent Insys tumbling as the website stated that according to an affidavit from Marc Heggemeyer, a special agent for the U.S. Department of Health and Human Services, Office of Inspector General, Office of Investigations, Awerbuch was responsible for approximately 20.3% of Subsys scrips prescribed to Medicare beneficiaries in the U.S. in the Jan 2009 to Feb 2014 time period.

The Clarifying Statement

In response to this news, Insys issued a clarifying statement. Insys stated that it takes patient safety seriously and works with physicians for the proper prescribing and use of Subsys. The company also said that the transmucosal immediate release fentanyl risk evaluation and mitigation strategy (REMS) access program governs Subsys. The REMS program ensures appropriate use of the drug. Subsys is indicated for breakthrough pain in opioid-tolerant cancer patients.

The company also went on to say that it has broadened its prescriber base so far in 2014, with no single physician writing more than 5% of total Subsys prescriptions.

Our Take

We note that Subsys is an important product for Insys. It generated 96.5% of the company's total sales in 2013. We believe that any negative development regarding Subsys will impact the company severely. However, the current concerns seem to be temporary.

Insys carries a Zacks Rank #2 (Buy). Some other stocks worth considering include Gilead Sciences Inc. ( GILD ), Affymetrix Inc. ( AFFX ) and Alexion Pharmaceuticals, Inc. ( ALXN ).  While Gilead carries a Zacks Rank #1 (Strong Buy), Alexion and Affymetrix hold a Zacks Rank #2.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AFFYMETRIX INC (AFFX): Free Stock Analysis Report

ALEXION PHARMA (ALXN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

INSYS THERAP (INSY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AFFX , ALXN , GILD , INSY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

106,679,460
  • $17.03 ▲ 0.47%
101,357,777
  • $38.65 ▼ 5.57%
61,830,117
  • $89.89 ▼ 4.26%
54,116,071
  • $5.11 ▼ 4.49%
50,121,934
  • $101.06 ▲ 0.10%
49,993,927
  • $3.52 ▼ 1.40%
47,717,687
  • $11.44 ▼ 4.67%
44,793,169
  • $99.05 ▼ 0.93%
As of 9/22/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com